相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study
Elena del Alcazar et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2020)
Ustekinumab treatment for moderate to severe psoriasis. Eight-year real-world follow-up of 61 cases in a tertiary level hospital
L. Elberdin et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2020)
Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)
S. K. Mahil et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Can the dose and dosing interval of biologics be optimized?
A. Morita et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ
M. Masson Regnault et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience
M. Galluzzo et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Ustekinumab in psoriasis: Five-year real life experience from a single tertiary centre
Ersoy Acer et al.
DERMATOLOGIC THERAPY (2020)
Psoriasis: Which therapy for which patient Psoriasis comorbidities and preferred systemic agents
Shivani B. Kaushik et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Ustekinumab in Real-Life Practice: Experience in 116 Patients with Moderate-To-Severe Psoriasis
Ines Raposo et al.
ACTA MEDICA PORTUGUESA (2019)
Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis
Tomaz Lunder et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2019)
Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines
Ketty Peris et al.
EUROPEAN JOURNAL OF CANCER (2019)
Drug survival of biologic treatments in psoriasis: a systematic review
Daniel J. No et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2018)
Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis
A. Egeberg et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Five-year experience with Ustekinumab for psoriasis: real-life data of a single centre
T. Vergou et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
A. Menter et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2016)
Long-Term Efficacy, Safety and Drug Survival of Ustekinumab in a Spanish Cohort of Patients with Moderate to Severe Plaque Psoriasis
Lluis Puig et al.
DERMATOLOGY (2015)
Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Richard B. Warren et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study
A. B. Kimball et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)
The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis
Lauren Young et al.
AUSTRALASIAN JOURNAL OF DERMATOLOGY (2012)
Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the UK and Ireland
P. M. Laws et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection
T. -F. Tsai et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Ustekinumab in clinical practice: response depends on dose and previous treatment
V. Ruiz Salas et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2012)
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives
Newman Yeilding et al.
PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: WINNERS AND FINALIST CANDIDATES OF THE PRIX GALIEN USA, INTERNATIONAL, AND PRO BONO HUMANITARIAN AWARDS 2010 (2011)
Ustekinumab A Review of its Use in the Management of Moderate To Severe Plaque Psoriasis
Jamie D. Croxtall
DRUGS (2011)
Micronodular basal cell carcinoma: A distinct subtype? Relationship with nodular and infiltrative basal cell carcinomas
Roberto Betti et al.
JOURNAL OF DERMATOLOGY (2010)
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Christopher E. M. Griffiths et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Ustekinumab: Lessons Learned from Targeting Interleukin-12/23p40 in Immune-Mediated Diseases
Michael Elliott et al.
CYTOKINE THERAPIES: NOVEL APPROACHES FOR CLINICAL INDICATIONS (2009)
Guidelines for the management of basal cell carcinoma
N. R. Telfer et al.
BRITISH JOURNAL OF DERMATOLOGY (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A. Papp et al.
LANCET (2008)
Verrucous carcinoma of the axilla: case report and review
C Assaf et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2004)
分享论文
